IDEAYA Biosciences (IDYA) Gets a Buy from Citi
Citi analyst Yigal Nochomovitz maintained a Buy rating on IDEAYA Biosciences with a $90 price target, while shares closed at $33.69. Mizuho Securities also issued a Buy rating, whereas TR reiterated a Hold rating. Nochomovitz, covering the Healthcare sector, has a 4.7% average return and a 39.51% success rate on recommended stocks.
Citi analyst Yigal Nochomovitz maintained a Buy rating on IDEAYA Biosciences on December 2 and set a price target of $90.00. The company’s shares closed yesterday at $33.69.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Neurocrine, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 4.7% and a 39.51% success rate on recommended stocks.
In addition to Citi, IDEAYA Biosciences also received a Buy from Mizuho Securities’s Graig Suvannavejh in a report issued on December 2. However, on November 18, TR | OpenAI – 4o reiterated a Hold rating on IDEAYA Biosciences (NASDAQ: IDYA).
